RT @JohnEbbenMDPhD
☘️ A huge thank you to @JVentoMD & @brian_rini for taking us through the sometimes confusing data around adjuvant IO in #RCC at #TumorBoardTuesday. Shared decision making based on risk factors is key in #kidneycancer! ☘️ https://twitter.com/JohnEbbenMDPhD/status/1636548171160485889

☘️ A huge thank you to @JVentoMD & @brian_rini for taking us through the sometimes confusing data around adjuvant IO in #RCC at #TumorBoardTuesday. Shared decision making based on risk factors is key in #kidneycancer! ☘️
---
RT @JohnEbbenMDPhD
@TumorBoardTues @brian_rini @JVentoMD @MPishvaian @Uromigos @JoshLangMD @renalandurology @UroDocAsh 3/5 #TumorBoardTuesday
Thurs Case🎀

🎥 TBT in a video
High risk #RCC, pembro= DFS advantage, …
https://twitter.com/JohnEbbenMDPhD/status/1636548171160485889

RT @JVentoMD
@MPishvaian @TumorBoardTues @brian_rini @montypal @PGrivasMDPhD @rafee_talukder @shilpaonc @DrYukselUrun @TiansterZhang @KidneyCancer @HHammersMD @arihakimi @RCCadvocate @QingZhangLab @DrRanaMcKay @DrScottHaake @MVossMD @archie_hh @DrTanWP @mtsiatas @sonpavde Of course, this is a great thing in that our #kidneycancer patients are having wonderful outcomes!

RT @JVentoMD
@MPishvaian @TumorBoardTues @brian_rini @montypal @PGrivasMDPhD @rafee_talukder @shilpaonc @DrYukselUrun @TiansterZhang @KidneyCancer @HHammersMD @arihakimi @RCCadvocate @QingZhangLab @DrRanaMcKay @DrScottHaake @MVossMD @archie_hh @DrTanWP @mtsiatas @sonpavde Of course, this is a great thing in that our #kidneycancer patients are having wonderful outcomes!

RT @JVentoMD
@MPishvaian @TumorBoardTues @brian_rini @montypal @PGrivasMDPhD @rafee_talukder @shilpaonc @DrYukselUrun @TiansterZhang @KidneyCancer @HHammersMD @arihakimi @RCCadvocate @QingZhangLab @DrRanaMcKay @DrScottHaake @MVossMD @archie_hh @DrTanWP @mtsiatas @sonpavde Of course, this is a great thing in that our #kidneycancer patients are having wonderful outcomes!

RT @drmehrarohit@twitter.com

Check out our study on intense intratumoral heterogeneity in clear cell RCC with biomarker/clinical annotations- Thanks to all collaborators🙏 @UMichPath@twitter.com @UMRogelCancer@twitter.com @Human_Pathology@twitter.com #gupath #kidneycancer #PathTwitter https://pubmed.ncbi.nlm.nih.gov/36511267/ Free link https://authors.elsevier.com/a/1gAOvAfIPi6o8

🐦🔗: https://twitter.com/drmehrarohit/status/1603815280869883913

RT @LauraEsfeller
Out of NOWHERE sometimes!! Excellent point on side effect management for #renalcellcarcinoma #kidneycancer https://twitter.com/mpishvaian/status/1602481030551814144

RT @dawood_findakly
We described some of the toxicities from anti-VEGF therapies used in metastatic renal cell carcinoma @JCO_ASCO 👉https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e16533
@ASCO #RCCsm #kidneycancer #OncTwitter #MedTwitter #CancerResearch https://twitter.com/shilpaonc/status/1602842736230649859

RT @NCIResearchCtr@twitter.com

✒️#APPLYNOW The @theNCI@twitter.com is seeking an outstanding, internationally recognized, and visionary clinician-scientist to lead CCR's @nciccr_gmb@twitter.com https://ccr.cancer.gov/genitourinary-malignancies-branch! #ProstateCancer #KidneyCancer #BladderCancer
Learn more about this #CareerOpportunity here https://ccr.cancer.gov/careers/chief-genitourinary-malignancies-branch/25604

🐦🔗: https://twitter.com/NCIResearchCtr/status/1595490372616130585

Hello Urology people! We have moved and are now under medics ☺️

We are here to listen and share for #Urology #ProstateCancer #BladderCancer #KidneyCancer #PenileCancer #TesticularCancer #UTUC #RCC #Urolithiasis #KidneyStones #Endourology #OAB #Incontinence #InterstitialCystitis #PedUro #KidneyTransplant #UroUTI #UroBPH #ReconstructiveUrology #UroTrauma #PeyroniesDisease #ErectileDysfunction #Andrology #LUTS #Priapism #Infertility #PelvicFloor #RenalTrauma #SexualMedicine #UroSoMe

RT @_ShankarSiva@twitter.com

🧵1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol@twitter.com; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect@twitter.com for 50-day link: #radonc #kcsm https://www.sciencedirect.com/science/article/pii/S1470204522006568?dgcid=author

🐦🔗: https://twitter.com/_ShankarSiva/status/1592729843283955712

Excellent 5-yr data on patients receiving stereotactic ablative radiotherapy for primary kidney cancer!

RT @_ShankarSiva@twitter.com

🧵1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol@twitter.com; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect@twitter.com for 50-day link: #radonc #kcsm https://www.sciencedirect.com/science/article/pii/S1470204522006568?dgcid=author

🐦🔗: https://twitter.com/_ShankarSiva/status/1592729843283955712

Re #introduction

Hey everyone, I'm Prathyusha, a postdoc at Dana-Farber/Harvard Medical School. My PhD research was in #cancer #immunology and my current research interests are in #immunology and #genetics of #kidneycancer

I enjoy reading and painting as a hobby.

I mostly toot about science and occasionally you'll find random musings, food, and paintings (though life has been too busy lately to focus on the last).

Here to meet the fun #academic and #scientific community! #ScienceMastodon

RT @NicholasZaorsky
Kidney cancer staging in one figure.

#KidneyCancer
@AJCCancer 8th ed